- A phase 2 study of salvage chemotherapy with etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) found modest activity and an acceptable safety profile in patients with refractory or relapsed Hodgkin's lymphoma (HL).
Why this matters
- Guidance is lacking on how to treat refractory or relapsed HL.
- The findings reported here suggest that ESHAOx is a feasible option.
- Open-label, nonrandomized, multicenter trial of ESHAOx in Korea (N=36).
- Patients with refractory or relapsed HL were given ESHAOx, consisting of intravenous (IV) etoposide 40 mg/m2 on days 1 to 4, IV methylprednisolone 500 mg on days 1 to 5, IV cytarabine 2 g/m2 on day 5, and IV oxaliplatin 130 mg/m2 on day 1; up to 6 cycles were repeated every 3 weeks.
- Funding: National Cancer Center, Goyang, Korea.
- Objective response rate, 72.2% (33.3% complete and 38.9% partial).
- Median time to progression, 34.9 (95% CI, 23.1-46.7) months.
- Most common grade 3 or 4 hematologic adverse events:
- Neutropenia, 43.2%.
- Thrombocytopenia, 27.0%.
- Most common grade 3 or 4 nonhematologic adverse events:
- Nausea, 8.1%.
- Anorexia, 5.4%.
- Mucositis, 2.7%.
- Skin rash, 2.7%.
- Poorer OS was associated with high serum levels of cytokines tumor necrosis factor-α (P=.00005) and C-reactive protein (P=.0004).
- Nonrandomized, open-label design.
- No control group.